

DELON RESOURCES CORP.
Suite 1980, 1075 West Georgia Street
Vancouver, British Columbia, V6E3C9
Telephone: (604) 688-9588; Fax: (778)
329-9361

GENER8 DIGITAL MEDIA CORP.
Suite 9-375 Water Street
V6B 5C6, Canada
Tel: (604) 669 8885
Fax: (604) 669 8855

JOINT PRESS RELEASE

NOT FOR DISTRIBUTION TO U.S. NEWSWIRE SERVICES OR DISSEMINATION
IN THE UNITED STATES

AGREEMENT TO ACQUIRE GENER8 DIGITAL MEDIA CORP.

VANCOUVER, BRITISH COLUMBIA, October 19, 2012 – Delon Resources Corp. (CNSX: DLN) (the “Company”) and Gener8 Digital Media Corp. (“Gener8”) are pleased to announce that they have entered into a binding letter agreement (the “Agreement”) pursuant to which the Company will acquire all of the issued and outstanding common shares of Gener8 (the “Transaction”) in consideration of 20,000,000 common shares of the Company. The Transaction, will take place by way of a plan of arrangement, share exchange, and/or other similar transaction which will result in Gener8 becoming a wholly-owned subsidiary of the Company or otherwise combining its corporate existence with that of the Company and will constitute a “fundamental change” for the Company under the policies of the Canadian National Stock Exchange (the “CNSX”).

Gener8 Digital Media Corp. is a private B.C. based media technology company with two business divisions, Gener8 Studio and Cumul8™ Technology. In less than two years, Gener8’s studio division has become an industry leader in 3D stereo conversion services for the entertainment industry, working on high profile films such as The Amazing Spider-Man and Harry Potter and the Deathly Hollows Part 2. The Gener8 studio division uses its proprietary G83D™ technology process to convert traditionally-produced media into an immersive 3D stereoscopic experience for 3D production.

The newly launched Cumul8™ technology division provides cloud-based live information control solutions to the entertainment industry and beyond. This solution goes into any and all data based information systems and gives the client 24/7 live control of the data they need on any device, from anywhere. Today Cumul8 is already being used to manage the distribution of Hollywood’s digital data, effectively controlling data flow and giving studios the business intelligence to drive down costs throughout their production. The service, which Gener8 has been using internally and evolving since the company’s formation, is now available commercially to a growing market.

Gener8’s head office is located in Vancouver, British Columbia and has approximately 75 employees across both divisions. The executive team draws on years of experience developing graphics technology in commercial software, video games and the film industry.

Concurrent with the closing of the Transaction (the “**Closing Date**”), the Company will consolidate its shares on the basis of 1 new for each 2 pre-existing shares of the Company and will issue to the shareholders of Gener8, on a pro rata basis, that number of common shares of the Company such that, prior to the completion of the Concurrent Financing (as defined below) and on an undiluted basis, current shareholders of Gener8 will hold approximately 78.3% of the issued and outstanding post-consolidated common shares of the Company and the former shareholders of the Company will hold 21.7% of the issued and outstanding common shares of the Company. Under the terms of the Agreement all issued and outstanding options, warrants and other convertible securities of Gener8 will be replaced with the equivalent option, warrants or other convertible securities of the Company which are to be convertible into Company common shares on the same ratio as the Company common shares to be issued in exchange for issued and outstanding common shares of Gener8 pursuant to the Transaction.

In connection with the Transaction, the Company intends to complete a private placement (the “**Concurrent Financing**”) for minimum gross proceeds of \$5,000,000. The pricing and terms for the Concurrent Financing will be determined by both parties, subject to the applicable rules and regulations. The Concurrent Financing will be completed by way of a private placement, in reliance on applicable prospectus exemptions pursuant to National Instrument 45-106. In connection with the Concurrent Financing, the Company will pay a finder’s fee in cash, securities or a combination of both, up to the maximum amount permitted by the CNSX, as applicable.

As a condition of closing of the Transaction a finder’s fee of 900,000 Company common shares will be paid to Mauris Financial Corp. subject to applicable regulatory and CNSX approval. The completion of the Transaction is subject to a number of additional conditions, including, but not limited to, the execution of a definitive agreement, completion of satisfactory due diligence, approval of the Transaction by the board of directors and, if applicable, shareholders of each of the Company and Gener8, the completion of the Concurrent Financing for minimum gross proceeds of \$5,000,000, completion of the consolidation, and the approval of the CNSX. There can be no assurance that the Transaction will be completed as proposed, or at all and trading in the Company’s securities should be considered highly speculative.

Bridge Loan

In connection with the Agreement, the Company has advanced Gener8 an unsecured loan in the amount of \$300,000 (the “**Bridge Loan**”). The Bridge Loan is for a term of one year commencing on the date of execution of the Agreement and is payable in a lump sum at the end of the term. The Bridge Loan bears interest at a rate of 8% per annum.

ON BEHALF OF THE BOARD

“Herrick Lau”

Herrick Lau

Chief Executive Officer and Director

FOR MORE INFORMATION, PLEASE CONTACT:

Herrick Lau
herrick.lau@barongroupintl.com
604-688-9588

The CNSX does not accept responsibility for the adequacy or accuracy of this release.

The securities referred to in this news release have not been, nor will they be, registered under the United States Securities Act of 1933, as amended, and may not be offered or sold within the United States or to, or for the account or benefit of, U.S. persons absent U.S. registration or an applicable exemption from the U.S. registration requirements. This news release does not constitute an offer for sale of securities for sale, nor a solicitation for offers to buy any securities. Any public offering of securities in the United States must be made by means of a prospectus containing detailed information about the company and management, as well as financial statements

Forward Looking Statements

Except for historical information contained herein, this news release contains forward-looking statements that involve risks and uncertainties. Actual results may differ materially. Except as required pursuant to applicable securities laws, Delon will not update these forward-looking statements to reflect events or circumstances after the date hereof. More detailed information about potential factors that could affect financial results is included in the documents filed from time to time with the Canadian securities regulatory authorities.